Swiss Life Asset Management Ltd Has $6.11 Million Holdings in STERIS plc $STE

Swiss Life Asset Management Ltd lifted its stake in shares of STERIS plc (NYSE:STE) by 35.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,697 shares of the medical equipment provider’s stock after purchasing an additional 6,433 shares during the period. Swiss Life Asset Management Ltd’s holdings in STERIS were worth $6,111,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. boosted its position in STERIS by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock valued at $3,022,114,000 after buying an additional 50,393 shares during the last quarter. State Street Corp increased its position in STERIS by 4.0% in the third quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider’s stock worth $1,077,564,000 after purchasing an additional 166,736 shares during the period. Orbis Allan Gray Ltd increased its position in STERIS by 36.0% in the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after purchasing an additional 556,088 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of STERIS by 16.4% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock worth $387,797,000 after buying an additional 221,199 shares during the period. Finally, Invesco Ltd. raised its stake in shares of STERIS by 4.9% during the third quarter. Invesco Ltd. now owns 1,280,142 shares of the medical equipment provider’s stock worth $316,758,000 after buying an additional 59,443 shares during the last quarter. 94.69% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on STE shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.20.

Insider Transactions at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. This represents a 81.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.07% of the company’s stock.

STERIS Stock Performance

Shares of STERIS stock opened at $220.24 on Friday. The company has a market capitalization of $21.60 billion, a PE ratio of 30.72 and a beta of 1.05. STERIS plc has a 12 month low of $204.90 and a 12 month high of $269.44. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $246.98 and its 200 day simple moving average is $249.58.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same period in the previous year, the business earned $2.32 earnings per share. The company’s revenue was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, research analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Investors of record on Tuesday, February 17th were given a $0.63 dividend. The ex-dividend date was Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. STERIS’s payout ratio is currently 35.15%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.